Myocardial Perfusion Imaging Adjunct — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for myocardial perfusion imaging adjunct. 3 active patents protecting 2 drugs from 2+ originators. First major cliff: 2034. Daily refresh.

2
Approved drugs
3
Active US patents
43/100
Avg vulnerability
—
Annual revenue covered

Originators in Myocardial Perfusion Imaging Adjunct

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 2 patents Roche Palo 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating myocardial perfusion imaging adjunct. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27
1
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Regadenoson Pfizer Inc. 2 44 — 2027-02-02
Cytovene
GANCICLOVIR
 Roche Palo 1 42 — 2034-09-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE47301 Regadenoson formulation 60 2027-02-02
9486530 Cytovene formulation 42 2034-09-02
8106183 Regadenoson composition of matter 27 2027-02-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8106183 Regadenoson composition of matter 27 2027-02-02
9486530 Cytovene formulation 42 2034-09-02
RE47301 Regadenoson formulation 60 2027-02-02

Related